No Detail Found!

Safety and efficacy of thalidomide in transfusion- dependent β-thalassemia: a systematic review and meta-analysis

Author(s)
Zahid Ali Department of Pharmacy, University of Peshawar, Peshawar, Pakistan.
Mohammad Ismail Department of Pharmacy, University of Peshawar, Peshawar, Pakistan.
Muhammad Tariq Masood Khan Department of Haematology, Pak International Medical College, Peshawar, Pakistan.
Inayat Ur Rahman Department of Pharmacology, Northwest School of Medicine, Peshawar, Pakistan
Abstract
OBJECTIVE: The current meta-analysis was carried out to identify the efficacy and safety of thalidomide in transfusion-dependent ß-thalassemia (TDT) patients. METHODS: Six databases: PubMed, EMBASE, Scopus, Cochrane Library, EBSCOhost, and MEDLINE were searched until November 18, 2021, for studies that assessed the efficacy of thalidomide in TDT patients by using the following searchterms : “ Thal idomid e ” , “ thalidomid ” , “ thalomid ” , “ N phthaloylglutamimide”, and Thalassemia” using Boolean or wildcard operators. Original research publications in English with observational and/or experimental designs having a sample size =10, regardless of age and gender, used thalidomide for =3 months exploring the impact of thalidomide in ameliorating transfusion needs among TDT patients were included in this meta-analysis. Data were independently extracted by two reviewers using a data extraction form. The National Institutes of Health tool was used for quality assessment. RESULTS: Nine studies collectively involving 407 TDT patients fulfilled eligibility criteria. Thalidomide was associated with complete cessation of blood transfusion requirements with an overall response of 54% (95% CI, 34-75%) to a transfusionindependent state; heterogeneity was considered high with an I2 of 94.7%, pvalue<0.001. Mild adverse events were reported in 44% of patients. CONCLUSION: Thalidomide is a well-tolerated, effective and safe drug among TDT patients, these findings, however, should be confirmed through well-designed clinical trials.
Publication Details
Page(s) 201-206
Published Journal: Khyber Medical University Journal, Volume: 14, Issue: 3, Year: 2022

Request the full text from PASTIC

Keywords
Anemia, Anemia, Efficacy (Non-MeSH), Hemolytic, Congenital (MeSH), Safety (MeSH), Thalidomide (MeSH), Transfusion-dependent ß-thalassemia (Non-MeSH), betaThalassemia (MeSH), Thalassemia (MeSH)
0

Citations

0

Downloads

25

Views